PE-backed SciClone achieves $1.6b market cap on HK re-listing
SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
The company sold approximately 115.9 shares at HK$18.80 apiece – the top end of the indicative range – to raise HK$2.18 billion in its IPO, according to a filing. Cornerstone investors covered nearly...
More on Greater China
Latest News
Riverside adds to Australia workplace wellbeing rollup play
The Riverside Group has bought Australian injury management and occupational rehabilitation services provider Nabenet as part of a workplace wellbeing rollup strategy.
China vacuum cleaner brand Dreame raises $563m
Dreame, a Beijing-headquartered vacuum cleaner maker backed by smart phone and consumer electronics giant Xiaomi, has raised RMB3.6 billion ($563 million) in Series C funding.
Primavera makes $600m China cleantech investment
Primavera Capital Group has invested $600 million in two subsidiaries of Envision Group, a China-based manufacturer of wind turbines, smart batteries, and renewable energy management systems.
India's Axis Bank seeks $468m for distress buyout fund
India’s Axis Bank has launched a distress buyout fund targeting INR35 billion ($468 million) via its asset management business.